DepoVax™ is a vaccine adjuvanting platform that works with a variety of vaccine antigens. DepoVax™ creates a unique depot that attracts antigen-presenting cells to the site to potentially generate a rapid and robust immune response. The DepoVax™ platform is chemically stable, flexible and forms the basis of Immunovaccine’s therapeutic cancer and infectious disease vaccines.
Upon injection, the depot vaccine remains at the site of immunization for a prolonged period of time. Exposure of antigen presenting cells to the optimized mixture of antigens and immune activators that make up each DepoVax™-based vaccine may allow for the generation of strong cellular and humoral immune responses, in as little as a single dose. All components of the DepoVax™ platform - the antigen plus adjuvant, encapsulated in a liposome and then resuspended in oil - are necessary for an optimal immune response. The DepoVax™ platform is commercially scalable, with potential for years of stability and ease of use in the clinic.
Benefits of the DepoVax™ platform include:
• Efficacious and flexible depot vaccine formulation
• Reduction in the number of doses required for efficacy from two or three to ONE and earlier onset of protection
• Multi-year antibody production and long-lasting cellular responses
• Strong and rapid immune response to a wide range of antigens
• Ability to prevent the growth of tumors in pre-clinical models with a single dose
• Ability to destroy cancer cells in pre-clinical models with a single dose (100% elimination)
• Effectively enhances the immunogenicity synthetic peptide antigens, ideally suited for the next generation of therapeutic and prophylactic vaccines
• Highly flexible format suitable for any type of antigen, including peptides, proteins and nucleic acids
• Dry storage formulation for enhanced stability of antigens
• Easy to reconstitute and administer
Immunovaccine has conducted promissing proof of concept studies in both cancer and infectious disease indications with its original VacciMax® and DepoVax™ platforms with highly promising results. The majority of the key data and peer reviewed publications are available in the Document Library.
Click Here to visit Immunovaccine's Document Library.
